Practical approach to the diagnosis and management of thrombocytopenia associated with tirofiban treatment

American Journal of Hematology

Volumn 77, Issue 1, 2004, Pages 67-71

  Mulot, Agnès ^a,b   Moulin, Frédéric ^a   Fohlen Walter, Anne ^a,b   Angioi, Michael ^a   Sghaier, Mohammed ^a   Carteaux, Jean Pierre ^a,b   Lecompte, Thomas ^a,b   De Maistre, Emmanuel ^a,b,c  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b INSERM   (France)

^c Service d'Hematologie Biologique   (France)

Author keywords

GPIIb IIIa inhibitor; Thrombocytopenia; Tirofiban

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; TIROFIBAN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CARDIOPULMONARY BYPASS; CASE REPORT; CORONARY ARTERY BYPASS SURGERY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; HIGH RISK PATIENT; HUMAN; MALE; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

AGED; DISEASE MANAGEMENT; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBOCYTOPENIA; TYROSINE;

EID: 4243116409     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20149     Document Type: Article

References (23)

1. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002;359:189-198.
2. Karvouni E, Katritsis DG, Ioannidis J. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol 2003;41:26-32.
3. Dasgupta H, Blankenship JC, Wood GC, Frey CM, Demko L, Menapace FJ. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Am Heart J 2000;140:206-211.
4. Tcheng JE. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and re-treatment. Am Heart J 2000;139:S38-S45.
5. Stone GW, Moliterno DJ, Bertrand M, et al. Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET trial. Circulation 2002;105:2347-2354.
6. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after c7E3 Fab (Abciximab) therapy. Circulation 1997;95:809-813.
7. Jubelirer SJ, Koenig BA, Bates MC. Acute profound thrombocytopenia following C7E3 Fab (Abciximab) therapy: case reports, review of the literature and implications for therapy. Am J Hematol 1999;61:205-208.
8. Bougie DW, Wilker PR, Wuitschick ED, et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 2002;100:2071-2076.
9. Nagge J, Jackevicius C, Dzavik V, Ross JR, Seidelin P. Acute profound thrombocytopenia associated with eptifibatide therapy. Pharmacotherapy 2003;23:374-379.
10. Rezkalla SH, Hayes JJ, Curtis BR, Aster RH. Eptifibatide-induced acute profound thrombocytopenia presenting as refractory hypotension. Cathet Cardiovasc Intervent 2003;58:76-79.
11. Salengro E, Mulvihill NT, Farah B. Acute profound thrombocytopenia after use of eptifibatide for coronary stenting. Cathet Cardiovasc Intervent 2003;58:73-75.
12. Wool RL, Coleman TA, Hamill RL. Abciximab-associated pseudothrombocytopenia. Am J Med 2002;113:697-698.
13. Lecompte T, Stieltjes N, Shao-Kai L, Morel MC, Kaplan C, Samama MM. Heparin- and streptokinase-dependent platelet-activating immunoglobulin G: mechanism and diagnosis. Semin Thromb Haemost 1995;21:95-105.
14. Amiral J, Bridey F, Wolf M, et al. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb Haemost 1995;73:21-28.
15. Trossaërt M, Gaillard A, Commin PL, Amiral J, Wissac AM, Fressinaud E. High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery. Br J Haematol 1998;101:653-655.
16. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 1998;79:1-7.
17. Pouplard C, Amiral J, Borg JY, Laporte-Simitsidis S, Delahousse B, Gruel Y. Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1999;111:700-706.
18. George JN, Raskob GE, Rizvi Shah S, et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 1998;129:886-890.
19. Llevadot J, Coulter SA, Giugliano RP. A practical approach to the diagnosis and management of thrombocytopenia associated with glycoprotein IIb/IIIa receptor inhibitors. J Thromb Thrombolysis 2000;9:175-180.
20. Curtis B, Swyers J, Divgi A, McFarland J, Aster R. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood 2002;99:2054-2059.
21. Desai M, Lucore CL. Uneventful use of tirofiban as an adjunct to coronary stenting in a patient with a history of abciximab-associated thrombocytopenia 10 months earlier. J Invasive Cardiol 2000;12:109-112.
22. Simon BC, Herzum M, Klisch A, et al. Acute severe thrombocytopenia after c7E3 Fab (abciximab) therapy in a patient with unstable angina and stenting of the right coronary artery. Occurrence of subacute stent thrombosis and safe readministration of the GPIIb/IIIa inhibitor tirofiban. Int J Cardiovasc Intervent 2000;3:185-188.
23. Coto H. Platelet receptor glycoprotein IIb/IIIa inhibition with eptifibatide in a patient with thrombocytopenia after treatment with abciximab. J Invasive Cardiol 2000;12:528-531.